Effect of Recombinant Human Brain Natriuretic Peptide on Hemodynamics and Drug Safety in Patients with Severe Cardiac Valvular Disease

  • Min Zhou
Keywords: Recombinant human brain natriuretic peptide; Valvular heart disease; Hemodynamics; Medication safety

Abstract

This paper analyse the effect of recombinant human brain natriuretic peptide (rh-BNP) on postoperative hemodynamics in patients with severe heart valvular disease and its safety. The control group was given conventional cardiotonic and vasodilator drugs. The observation group was given rh-BNP and cardiotonic drugs but not vasodilator drugs. The changes of standard (BNP, ET-1, NE) and echocardiography (LVEDD, LVEF) were recorded, and all adverse events were recorded to evaluate the drug safety. After 4 hours, the PCWP level of the observation group was significantly lower than that of the control group (P < 0.05); after 30 minutes, the mPAP level of the observation group was significantly lower than that of the control group (P < 0.05); after 1, 2, 4 hours, the cardiac index of the observation group was gradually increased, and the observation group was significantly higher than that of the control group (P < 0.05); PVR decreased significantly 2 hours after treatment, significantly lower than the control group (P < 0.05); CVP and ABG slightly increased in the control group, the observation group was basically stable, there was no significant difference between the two groups (P > 0.05); after treatment, the biochemical indicators of the two groups were significantly reduced, the observation group was lower than the control group (P < 0.05); There was no significant difference between the two groups (P > 0.05); LVEF index in the observation group was significantly higher than that in the control group (P < 0.05); there was no significant difference in adverse drug events between the two groups (P > 0.05). Recombinant human brain natriuretic peptide can significantly improve the postoperative hemodynamic effects in patients with severe heart valve disease, thereby improving cardiac function without increasing adverse drug reactions.

Published
2019-09-01